Skip to main content
. Author manuscript; available in PMC: 2022 Nov 14.
Published in final edited form as: J Allergy Clin Immunol. 2022 Jun 27;150(5):1097–1105.e12. doi: 10.1016/j.jaci.2022.05.024

FIGURE 2:

FIGURE 2:

Surface under the cumulative ranking (SUCRA) curve with regard to the efficacy outcomes, exacerbation and prebronchodilator forced expiratory volume in 1 second (FEV1), in individuals with eosinophil count of 150–299 cells per microliter. Each plot displays the cumulative ranking probabilities of each treatment being the best (#1), second-best (#2), third-best (#3), or the worst (#4) for each outcome. The best overall treatment would be the treatment with its area under curve closest to the entire area of the graph shaped a rectangle. For example, benralizumab and dupilumab ranked higher than mepolizumab which ranked higher than placebo in reducing exacerbations and improving FEV1 in these patients.